Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

molnlycke health care pty ltd - 46855 - dressing, wound-nonadherent, permeable - mepitel one is a wound contact layer designed for the management of a wide range of exuding wounds such as; skin tears, skin abrasions, surgical incisions, partial thickness burns, traumatic wounds, partial and full thickness grafts, radiated skin, leg and foot ulcers. it can also be used as a protective layer on non-exuding wounds, blisters and on areas with fragile skin

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

janssen biotech, inc. - abciximab (unii: x85g7936gv) (abciximab - unii:x85g7936gv) - abciximab 2 mg in 1 ml - abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications - in patients undergoing percutaneous coronary intervention - in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours safety and efficacy of abciximab use in patients not undergoing percutaneous coronary intervention have not been established. abciximab is intended for use with aspirin and heparin and has been studied only in that setting, as described in clinical studies. because abciximab may increase the risk of bleeding, abciximab is contraindicated in the following clinical situations: - active internal bleeding - recent (within six weeks) gastrointestinal (gi) or genitourinary (gu) bleeding of clinical significance - history of cerebrovascular accident (cva) within two years, or cva with a significant residual neurological deficit - bleeding diathesis - administration of oral anticoagulan

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

eli lilly and company - abciximab (unii: x85g7936gv) (abciximab - unii:x85g7936gv) - abciximab 2 mg in 1 ml

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

janssen biologics b.v. - abciximab - solution for inj/inf - 2 mg/ml - platelet aggregation inhibitors excl. heparin

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - abciximab - solution for injection - 2mg/1ml

Armeenia - inglise - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline biologicals s.a. - human papillomavirus type 16 l1 protein, human papillomavirus type 18 l1 protein - suspension for injection - 20mcg/dose+ 20mcg/dose